Following the successful completion of its deal to acquire GSK’s opiates business in Australia, Sun Pharmaceutical Industries Ltd has begun the process of integration of the acquired business. This deal, first announced in March 2015, fortifies Sun Pharma’s global position with two opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.
Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialised team to drive business growth. Opiates are any of the opioid analgesic alkaloids found as natural products in the opium poppy plant, Papaver somniferum.
The opiates acquisition allows Sun Pharma to significantly expands its narcotics raw material (NRM) market share; enhance opiate alkaloids portfolio & depth in global opiates market; and strengthen its strategic position in the global opiates business.
Anil Kumar Jain, CEO – API business, Sun Pharma, said, “The successful completion of this acquisition enables us to leverage our unique position in the global opiates business by capitalising our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation.”
Source: Business Standard
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
